A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4
Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placeb...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | anglès |
| Publicat: |
2025
|
| Accés en línia: | https://doi.org/10.1183/13993003.02231-2024 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Sigues el primer a deixar un comentari!